tiprankstipranks
Trending News
More News >
C'BON COSMETICS Co., Ltd. (JP:4926)
:4926
Japanese Market

C'BON COSMETICS Co., Ltd. (4926) AI Stock Analysis

Compare
0 Followers

Top Page

JP:4926

C'BON COSMETICS Co., Ltd.

(4926)

Select Model
Select Model
Select Model
Neutral 58 (OpenAI - 5.2)
Rating:58Neutral
Price Target:
¥1,383.00
▲(16.41% Upside)
Action:ReiteratedDate:12/30/25
The score is driven primarily by solid financial stability from a debt-free balance sheet, offset by weak cash flow (negative operating and deeply negative free cash flow). Technicals are neutral-to-mixed, while valuation is reasonable with a moderate dividend yield and mid-range P/E.
Positive Factors
Conservative Balance Sheet
A debt-free balance sheet with a large equity cushion materially reduces refinancing and solvency risk. This durable strength preserves strategic optionality for investment or restructuring, and provides a buffer through demand cycles without immediate external financing pressure.
High Gross Margins
A sustained gross margin near 76% indicates strong product economics and potential pricing power in skincare. If management can improve operating leverage, that gross margin provides a structural runway to convert sales into sustainable operating profit over time.
Service-Driven Recurring Demand
A business model combining product sales with in-store counseling and beauty services creates customer stickiness and recurring revenue. The service layer drives repeat visits and cross-selling, supporting durable revenue streams and differentiated customer relationships versus pure retail.
Negative Factors
Weak Cash Generation
Persistent negative operating and sharply negative free cash flow raise execution and liquidity risk. Even with no debt, continued cash burn forces reliance on external funding or asset draws, constraining reinvestment, dividends, and making long-term strategic moves more difficult.
Thin & Volatile Profitability
Very thin operating and net margins leave little buffer against cost shocks or demand weakness. Combined with historical swings between losses and modest profits, this volatility undermines predictability of earnings and limits the company's ability to sustainably self-fund growth.
Low Returns on Equity
Low and inconsistent ROE signals that the company struggles to convert its sizable equity base into attractive earnings. Over the medium term this suggests suboptimal capital allocation and raises questions about long-term shareholder return potential absent structural improvement.

C'BON COSMETICS Co., Ltd. (4926) vs. iShares MSCI Japan ETF (EWJ)

C'BON COSMETICS Co., Ltd. Business Overview & Revenue Model

Company DescriptionC'BON COSMETICS Co.,Ltd. manufactures and sells cosmetics, quasi-drugs, and beauty appliance products. It offers various products, such as cleansing, lotion, cream, face wash, serum, and makeup base products. The company was founded in 1966 and is headquartered in Kawasaki, Japan.
How the Company Makes MoneyC'BON COSMETICS Co., Ltd. generates revenue through the direct sale of its cosmetics products, which include skincare creams, lotions, and other personal care items. The company primarily sells its products through a network of retail stores, online platforms, and beauty salons. Revenue is largely driven by consumer demand for high-quality skincare solutions and the company's ability to maintain strong relationships with retail partners. Additionally, C'BON COSMETICS may engage in strategic partnerships with other brands or entities to expand its market reach and enhance its product offerings. The company's earnings are significantly influenced by its brand reputation, product innovation, and effective marketing strategies.

C'BON COSMETICS Co., Ltd. Financial Statement Overview

Summary
Balance sheet strength is a key positive (no debt and solid equity cushion), but operating quality is mixed: profitability rebounded in 2025 to positive net and operating income with thin margins, while cash generation is a major weakness with negative operating cash flow and sharply negative free cash flow in 2025.
Income Statement
56
Neutral
Revenue has been broadly stable with a modest rebound in 2025 (+2.76% YoY) after declines in 2023 and a flat 2024. Profitability improved materially in 2025, returning to positive net income (¥136m) and positive operating profit, but margins remain thin (net margin ~1.5%, operating margin ~1.6%), well below the stronger gross margin profile (~76%). Results also show meaningful volatility, with sizable losses in 2020–2021 and again in 2023, suggesting earnings are not yet consistently durable.
Balance Sheet
86
Very Positive
The balance sheet is conservatively positioned with essentially no financial leverage (debt-to-equity near zero and total debt at ¥0 in 2025), which materially reduces refinancing and solvency risk. Equity remains large relative to the asset base (¥5.7bn equity vs. ¥8.5bn assets in 2025), providing a cushion through downturns. The main weakness is low and volatile returns on equity (about 2.4% in 2025 following negative returns in 2023–2024), indicating the company has not been consistently converting its capital base into attractive earnings.
Cash Flow
34
Negative
Cash generation is the key pressure point. Operating cash flow turned negative in 2025 (−¥43m) after being positive in 2024 and 2022, indicating weaker cash conversion despite improved reported earnings. Free cash flow is consistently negative across most years and was sharply negative in 2025 (−¥927m), pointing to heavy cash outflows that are not being self-funded by operations. While free cash flow improved in 2024 versus 2023, the overall pattern suggests elevated ongoing cash needs and higher execution risk if negative free cash flow persists.
BreakdownTTMMar 2025Mar 2024Mar 2023Mar 2022Mar 2021
Income Statement
Total Revenue9.02B8.84B8.50B8.53B9.15B9.10B
Gross Profit6.91B6.74B6.40B6.34B7.10B6.92B
EBITDA404.41M292.59M168.64M-92.22M329.61M-345.64M
Net Income253.04M136.27M-26.35M-421.77M44.87M-621.87M
Balance Sheet
Total Assets8.67B8.52B8.81B8.84B9.56B9.56B
Cash, Cash Equivalents and Short-Term Investments2.54B2.65B3.63B3.98B2.80B2.32B
Total Debt0.000.004.24M13.27M22.30M25.20M
Total Liabilities3.00B2.82B3.15B3.13B3.36B1.97B
Stockholders Equity5.67B5.70B5.66B5.71B6.20B7.60B
Cash Flow
Free Cash Flow0.00-926.52M-313.38M-700.71M321.35M-829.87M
Operating Cash Flow0.00-43.16M278.19M-81.47M433.37M-694.00M
Investing Cash Flow0.00-849.16M-581.94M1.35B44.91M161.38M
Financing Cash Flow0.00-90.22M-31.20M-91.29M-6.73M-6.80M

C'BON COSMETICS Co., Ltd. Technical Analysis

Technical Analysis Sentiment
Positive
Last Price1188.00
Price Trends
50DMA
1278.16
Positive
100DMA
1236.89
Positive
200DMA
1198.60
Positive
Market Momentum
MACD
20.56
Positive
RSI
55.57
Neutral
STOCH
54.11
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4926, the sentiment is Positive. The current price of 1188 is below the 20-day moving average (MA) of 1327.85, below the 50-day MA of 1278.16, and below the 200-day MA of 1198.60, indicating a bullish trend. The MACD of 20.56 indicates Positive momentum. The RSI at 55.57 is Neutral, neither overbought nor oversold. The STOCH value of 54.11 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4926.

C'BON COSMETICS Co., Ltd. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (62)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
68
Neutral
¥2.25B-3.0412.96%
63
Neutral
¥6.91B12.522.38%-0.79%
63
Neutral
¥8.90B36.092.65%11.87%-31.02%
62
Neutral
$20.33B14.63-3.31%3.23%1.93%-12.26%
60
Neutral
¥6.52B8.181.59%-9.99%-35.06%
58
Neutral
¥5.69B-33.121.68%8.46%
52
Neutral
¥6.49B3.82-19.42%
* Consumer Defensive Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
JP:4926
C'BON COSMETICS Co., Ltd.
1,334.00
186.29
16.23%
JP:4918
Ivy Cosmetics Corporation
390.00
135.00
52.94%
JP:4925
HABA Laboratories, Inc.
1,825.00
6.09
0.33%
JP:4929
ADJUVANT HOLDINGS CO., LTD.
810.00
-17.87
-2.16%
JP:4934
Premier Anti-Aging Co., Ltd.
724.00
-172.00
-19.20%
JP:4936
AXXZIA, Inc.
357.00
-60.23
-14.43%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Dec 30, 2025